New analysis of post-marketing studies examines relationship between PrEP use and efficacy.

Friday, March 1, 2024 Toward a Deeper Understanding of Effective Oral HIV Pre-Exposure Prophylaxis Use in Cisgender Women Colorized transmission electron micrograph of HIV-1 virus particles (green) budding and replicating from an H9 T cell (burgundy). The virus particles are in various stages of maturity, which accounts for differences in shape. Captured at the NIAID Integrated Research Facility in Fort Detrick, Maryland. Credit: NIAID An analysis of combined data from 11 oral HIV PrEP demonstration projects, 5 of them NIH-funded, found that cisgender women with 7 PrEP doses/week or 4–6 PrEP doses/week had very low HIV incidence. The analysis suggests that brief dosing interruptions might not stop cisgender women from experiencing PrEP's benefits. More data are needed to fully understand the mechanisms by which oral PrEP prevents HIV in cisgender women, including on the relationship between dosing and tissue concentrations and HIV prevention efficacy. Inclusion of cisgender women in HIV prevention research across their lifespan and collection of these data helps regulators, clinicians and cisgender women make informed decisions regarding any potential dosing interruptions when using oral PrEP. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107